WHO Revises Biologic Drug Nomenclature, Replacing -mab Suffix with Structure-Based Stems for Dermatology Practice
Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.
Abstract
WHO revised biologic drug nomenclature, replacing the -mab suffix with new structure-based stems and introducing others for JAK/BTK inhibitors and oral peptide antagonists, impacting dermatology drug naming.